Bharat Biotech to spearhead CSIR-backed Covid-19 therapy efforts

Our Bureau New Delhi | Updated on May 08, 2020 Published on May 08, 2020


The Hyderabad-based Bharat Biotech International Limited (BBIL) would lead a project to develop human monoclonal antibodies as therapy for Covid-19 infection recently sanctioned by the Council of Scientific and Industrial Research (CSIR), the firm said in a statement on Friday.

The project brings together academia – the Pune-based National Centre for Cell Sciences and Indian Institute of Technology, Indore – and industry Gurrgram-based PredOmix Technologies and BBIL for meeting the public health emergency precipitated by Covid-19, which has infected nearly 59,000 Indians so far.

Although efforts are underway for developing drugs and vaccines for controlling the Covid-19 pandemic, these are slow and expensive processes with uncertainties. Therefore, an alternative therapeutic regimen for early deployment is critical, the statement said.


The present project aims at generating highly effective and specific human monoclonal antibodies that are capable of neutralising the SARS-CoV2 virus. Such virus-neutralising antibodies can block the spread of infection by binding to the virus and rendering it ineffective. Monoclonal antibody therapy is a highly effective and safe method.

“The purpose of vaccination is to protect the healthy against future infections, and it alone may not provide a complete solution. We feel the monoclonal antibody therapy will provide a viable option,” said Krishna Ella, Chairman & Managing Director Bharat Biotech.

“The question is of how to treat those individuals who are already infected? Plus, we do not yet know how effective an anti-SARS-CoV2 vaccine will be in the older people and those with co-morbidities. Given the large number of Indians suffering from hypertension, diabetes, and heart diseases, this becomes an important issue.” Ella added.

“While both Israel and The Netherlands have recently announced the development of virus-neutralising antibodies, our approach is to develop a powerful cocktail of neutralising antibodies that can also simultaneously block mutational variants of the virus. We are fast-tracking the development process, to make the antibodies available within the next six months and thus improve the treatment efficacy,” he said.

Published on May 08, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.